Inovio, University of Pennsylvania deal

The partners expanded for a third time a 2007 deal to include exclusive, worldwide rights to the university's preclinical synthetic vaccines against cancers with mutations in the Wilms tumor 1 (WT1) gene; infectious diseases, including Clostridium difficile; and biodefense pathogens, including Ebola. ...